Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?

Skałba, Piotr; Cygal, Anna; Madej, Paweł; Dąbkowska-Huć, Anna; Sikora, Jerzy; Martirosian, Gayane; Romanik, Małgorzata; Olszanecka-Glinianowicz, Magdalena

doi:10.1016/j.ejogrb.2011.06.006

Cited by 108 publications

(111 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are in accordance with previous studies that showed a significantly positive correlation between AMH and T or LH [Homburg et al 2013;Laven et al 2004;Pigny et al 2006;Skalba et al 2011]. However, none of these studies performed multiple regression analysis.…”

Section: Discussionsupporting

confidence: 82%

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Hua

et al. 2014

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

(2015) The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome, Systems Biology in Reproductive Medicine, 61:2, 103-109, DOI: 10.3109/19396368.2014.973123 To link to this article: https://doi.org/10. 3109/19396368.2014 AbstractThe aim of this study was to ascertain whether higher levels of serum anti-Mü llerian hormone (AMH) are associated with the ovarian follicular arrest in women with polycystic ovary syndrome (PCOS). This prospective study compared AMH levels between serum and dominant follicular fluid (FF) in ovulatory polycystic ovary (PCO) women and anovulatory (menstrual cycle !60 days.) PCOS women. All 102 women provided a baseline hormone profile and underwent controlled ovarian hyperstimulation (COH). The anovulatory PCO women had a similar body mass index (BMI), antral follicle count (AFC), and baseline serum AMH levels as the ovulatory PCO women except that their median luteinizing hormone (LH; 10.0 mIU/ml), testosterone (T) (0.61 ng/l), and androstenedione (A) (3.47 ng/l) levels were significantly higher than ovulatory PCO women (4.9 mIU/m; 0.43 ng/l and 2.09 ng/l, respectively). The ovarian response to gonadotropin stimulation during COH including serum AMH on the day of HCG administration and dominant FF AMH at 36 hours after HCG administration, total follicle stimulating hormone (FSH) dose administrated, peak E 2 , (estrogen) levels and number of occytes retrieved were all similar between women with anovulatory and ovulatory PCO. Using multiple regression analysis it was found that an important independent determinant affecting AMH was AFC, as opposed to LH and T. Logistic regression analysis showed that the two most important factors affecting ovulation were serum LH and T, whereas serum AMH and AFC were not selected for inclusion in the model. The reduction in AMH during COH occurs as a consequence of dominant follicles with a corresponding reduction in small antral follicle number. Elevated serum AMH levels in PCO women seem to be related only to follicular excess and not follicular arrest.

show abstract

Section: Discussionsupporting

confidence: 82%

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Hua

et al. 2014

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, the relationship between AMH and BMI still needs to be explored. Interestingly, HDL and LDL were significantly associated with AMH in our study, which was correspondent with another study [28]. It suggests that AMH may be not only a marker of ovarian function but also a potential new marker for cardiovascular diseases.…”

Section: Discussionsupporting

confidence: 76%

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Li¹,

Ma²,

Chen³

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of this study is to compare the secretory profiles and diagnostic power of anti-Mullerian hormone (AMH) for the PCOS patient with and without hyperandrogenism. Methods One hundred and thirty-one PCOS patients with oligomenorrhea or amenorrhea were recruited into the study. Sixty-two and sixty-nine patients had and did not have hyperandrogenism (HA+) hyperandrogenism (HA−), respectively. Sera were collected for determining the levels of AMH, basal sexual hormones, glucose and lipid metabolic indicators. Results The AMH serum levels of PCOS patients were significantly higher than the control group, with the highest AMH serum level in the HA+ group. The cut-off value for predicting PCOS patients of all types was 3.92 ng/mL, with a sensitivity of 65 %, and specificity of 62 %. The cut-off value for predicting PCOS patients in the HA+ group was 4.23 ng/mL, with a sensitivity of 82 %, and specificity of 64 %. The cut-off value for predicting PCOS patients in the HA− group was 3.76 ng/mL, with a sensitivity of 64 %, and specificity of 62 %. In the HA+ group, AMH was negatively associated with FSH and positively associated with LH. In the HA− group, AMH was negatively associated with HDL and positively associated with BMI, fasting glucose and LDL.Conclusions AMH is only suitable for predicting the PCOS patients with hyperandrogenism. The diagnostic power of AMH is limited when used to predict patients without hyperandrogenism. It reflects the differences in pathophysiology and severity of disrupted folliculogenesis between the two subtypes.

show abstract

“…Taking into account that PCOS women are commonly insulin resistant, the association between AMH and insulin resistance (IR) has been studied. Indirect measurements of IR have been associated with AMH either positively or negatively, or no association has been found [37,47,50]. Cassar et al, assessing IR by euglycaemic-hyperinsulinaemic clamp, did not find direct relationship between AMH and IR.…”

Section: Szkolenie Podyplomowementioning

confidence: 97%

Hormon anty-müllerowski i zespół policystycznych jajników

Łebkowska

Kowalska

2015

Endokrynologia Polska

View full text Add to dashboard Cite

Anti-Müllerian hormone (AMH) is a glycoprotein, a member of the transforming growth factor β family, reflecting the number of ovarian antral follicles. Polycystic ovary syndrome (PCOS) is a common endocrinopathy predisposing to infertility, and metabolic and cardiovascular complications. In our review, we discuss the role of AMH in PCOS pathophysiology and its clinical applications according to the published studies. Improvement of AMH assay validity will allow the clinical utility of this valuable biomarker to be widened.

show abstract

Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?

Cited by 108 publications

References 21 publications

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism

Hormon anty-müllerowski i zespół policystycznych jajników

Contact Info

Product

Resources

About